Safety and Efficacy of Percutaneous Parathyroid Ethanol Ablation in Patients with Recurrent Primary Hyperparathyroidism and Multiple Endocrine Neoplasia Type 1 | Zendy

Naykky Singh Ospina | Zendy; Geoffrey B. Thompson | Zendy; Robert A. Lee | Zendy; Carl C. Reading | Zendy; William F. Young | Zendy

Open Access

Safety and Efficacy of Percutaneous Parathyroid Ethanol Ablation in Patients with Recurrent Primary Hyperparathyroidism and Multiple Endocrine Neoplasia Type 1

Author(s) -

Naykky Singh Ospina,

Geoffrey B. Thompson,

Robert A. Lee,

Carl C. Reading,

William F. Young

Publication year - 2014

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2014-3255

Subject(s) - men1 , medicine , primary hyperparathyroidism , multiple endocrine neoplasia , hyperparathyroidism , surgery , endocrine system , gastroenterology , endocrinology , hormone , biochemistry , chemistry , gene

The most common feature of multiple endocrine neoplasia type 1 (MEN1) is primary hyperparathyroidism (PHP), which occurs in approximately 95% of MEN1 patients. Approximately 40-60% of patients with MEN1 develop recurrent hypercalcemia within 10-12 years after their initial parathyroid surgery and the successful management of recurrent PHP is challenging.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research